Medicare AdvantageCoverageHigh impact
MA08.072p, Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Mar 23, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated medical necessity criteria and coding requirements for Bevacizumab (Avastin®) and related biosimilars used in cancer treatment. This policy change affects oncology billing procedures and documentation requirements for these expensive cancer medications.
Action Required
Before March 23, 2026: Billing team must review and update procedures for Bevacizumab (Avastin®) and biosimilar claims to comply with new Medicare Advantage medical necessity criteria. Oncology providers must ensure documentation meets updated requirements. Review the full policy at the source URL to understand specific coding and documentation changes to prevent claim denials.